



Curriculum Vitae

Personal information **Joël Daems**

Work experience

1. Employer: RIZIV_INAMI
 - Start date: 022010
 - End date:
 - Position: HTA expert CTG_CRM
 - Activities: HTA for pharmaceutical specialties
 - Country: Belgium
2. Employer: Astellas Pharma BV
 - Start date: 052005
 - End date: 012010
 - Position: Medical Affairs Manager Transplantation
 - Activities: Medical Affairs Clinical trials phase II – IV (local centrum selection / financial agreements / CRA management / protocol development) – Medical representative training – Literature follow_up – Expert panel discussions – Regulatory support
 - Country: Belgium
3. Employer: Fujisawa
 - Start date: 032004
 - End date: 042005
 - Position: Medical Affairs Manager Transplantation_Dermatology
 - Activities: Medical Affairs Clinical trials phase II – IV (local centrum selection / financial agreements / CRA management / protocol development) – Medical representative training – Literature follow_up – Expert panel discussions – Regulatory support
 - Country: Belgium
4. Employer: NV Roche SA
 - Start date: 041999
 - End date: 022000
 - Position: Medical Affairs Manager Transplantation_Anemia
 - Activities: Medical Affairs Clinical trials phase II – IV (local centrum selection / financial agreements / CRA management / protocol development) – Medical representative training – Literature follow_up – Expert panel discussions – Regulatory support
 - Country: Belgium
5. Employer: AZ Maria Middelaars Sint_Niklaas / St Augustinus Wilrijk / AZ Jan Palfijn Merksem
 - Start date: 101996
 - End date: 031999
 - Position: Assistent specialist internal medicine
 - Activities: In_hospital internal medicine practice _cardiology_pneumology_gastroenterology_geriatrics_nephrology,...
 - Country: Belgium

Education and training

1. Subject: University of Antwerp
 - Start date: 101989
 - End date: 061996
 - Qualification: Medical Doctor
 - Organisation: Medicines
 - Country: Belgium

Additional information

Publications

• In recent_onset insulin_dependent diabetic patients GAD65 positivity is not associated with a significant increase of thyroid and gastric autoimmunity. I. De Leeuw, P. Abrams, J. Daems and the Belgian Diabetes Registry, Antwerp, Brussels, Belgium. EASD, 1996 • In new_onset insulin_dependent diabetic patients, GAD65Ab are not associated with local high risk HLA-DQ haplotypes and thyroid autoimmunity. L. Van Gaal, I. De Leeuw, P. Abrams, J. Daems and the Belgian Diabetes Registry. 10th International Congress of Endocrinology, 1996 • Effects of the constitutin of enteral tube feeding on the glycaemic index in the elderly. J. Daems, K. Van Winghem, I. De Leeuw, M. Vandewoude. Belgische Vereniging voor Gerontologie en Geriatrie, 20ste wintermeeting, Oostende, 1997. • Metabolic effects of 2 weeks enteral tube feeding in a geriatric population: comparative trial between Glucerna en Nutrison standard... J. Daems, K. Van Winghem, I. De Leeuw, M. Vandewoude. Jaarlijkse vergadering BGPNG en VVKNM, VUB, 1996. • Clinical outcome of a pilot study in primary renal transplantation investigating the feasibility of a low FK506/low_stop corticosteroid regimen in combination with daclizumab induction and mycophenolate mofetil. Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, D. Kuypers, M. Mourad, M. Meurisse, J. Daems. Abstract/Poster 529, ESOT, Lissabon, 2001. • Pharmacokinetic analysis of mycophenolate mofetil metabolites (MPA, MPAG, M2 and free_MPA) over a 6 month period post kidney transplantation using a low FK506/low_stop corticosteroid immunosuppressive regimen in combination with daclizumab and mycophenolate mofetil. D. Kuypers, Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, M. Mourad, H. Oellerich, J. Daems. Abstract/poster 676, ESOT, Lissabon, 2001. • Pharmacokinetic analysis of mycophenolate mofetil metabolites (MPA, MPAG, M_2 and free_MPA) over a 6 month period post primary kidney transplantation using a low FK506/low_stop corticosteroid immunosuppressive regimen in combination with daclizumab and mycophenolate mofetil. D. R. J. Kuypers, Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, M. Mourad, H. Oellerich, M. Shipkova, V. Armstrong, J. Daems. Abstract/poster, IATDMCT, Washington, 2001 • Pharmacokinetic analysis of mycophenolate mofetil metabolites (MPA, MPAG, M_2 and free_MPA) over a 6 month period post primary kidney transplantation using a low FK506

/low_stop corticosteroid immunosuppressive regimen in combination with daclizumab and mycophenolate mofetil. D. R. J. Kuypers, Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, M. Mourad, H. Oellerich, M. Shipkova, V. Armstrong, J. Daems. Ther. Drug Monit, 2001, 23: 467. • Daclizumab and mycophenolate mofetil allow for the use of low doses of tacrolimus and steroids in renal transplantation: a multi_center, pilot study in de novo renal transplantation. J._P. Squifflet, Y. Vanrenterghem, D. Abramowicz, D. Kuypers, M. Mourad, M. Meurisse, J. Daems. Abstract/poster, 2nd International Congress on Immunosuppression, San Diego, 2001. • Daclizumab and mycophenolate mofetil allow for the use of low dose s of tacrolimus and steroids in renal transplantation: A multi_center, pilot study in de novo renal transplantation. D. Abramowicz, Y. Vanrenterghem, J._P. Squifflet, M. Meurisse, D. Kuypers, M. Mourad, J. Daems. Abstract/poster A4574, ASN, San Francisco, 2001. • The pharmacokinetic analysis of mycophenolate mofetil metabolites (MPA, free_MPA, MPAG and M2) over a 6 month period post primary renal transplantation, using a low FK506/low_stop corticosteroid regimen with daclizumab induction and mycophenolate mofetil. D. Kuypers, Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, M. Mourad, H. Oellerich, J. Daems. Abstract/poster A4719, ASN, San Francisco, 2001. • The clinical outcome of a pilot study in primary renal transplantation investigating the feasibility of a low FK506/low_stop corticosteroid regimen in combination with daclizumab and mycophenolate mofetil to reduce cardiovascular immunosuppressive side_effects. Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, D. Kuypers, M. Mourad, M. Meurisse, J. Daems. Abstract/Poster, A1019, ATC, Washington, 2002. • The efficacy and side_effect profile of mycophenolate mofetil in renal transplant recipients in relation to different pharmacokinetic (PK) parameters and MMF metabolites: a 12 month multicenter trial. D. R. J. Kuypers, Y. Vanrenterghem, D. Abramowicz, J._P. Squifflet, M. Mourad, H. Oellerich, M. Shipkova, V. Armstrong, J. Daems. Abstract/oral presentation, A622, ATC, Washington, 2002. • Twelve_Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. Ther Drug Monit, 2003, 25(5):609_622

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)